Great isn't it? |
Am I the only one that's seen this hugely exciting news? £40m invested at a premium to a share price which has risen 112% YTD is some statement of intent |
 hxxps://polaris.brighterir.com/public/4basebio/news/rns/story/xekkqjx
"July 29, 2024 - 4basebio PLC (AIM: 4BB) ("4basebio" or the "Company"), which develops and commercialises the large scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, today announces that it has agreed to binding terms with (i) Elevage Medical Technologies ("Elevage"), a Patient Square Capital platform and (ii) Prudential Assurance Company Limited acting by its investment manager M&G Investment Management Limited ("M&G"), for a combined investment of £40.0 million through an issuance (the "Issuance") of ordinary shares of €1 each at an issue price of 1,500 pence per Ordinary Share (the "Issue Price")."
Dr Heikki Lanckriet, CEO and CSO, 4basebio, said: "The evolution of the Group since its spin out at the end of 2020 has been profound. Our client base and pipeline has grown significantly as a result of strong interest in our synthetic DNA products, and we expect client acquisition and revenue generation to continue accelerating.
"The capital raise announced today will further drive the momentum of the Company, and I am pleased to see Elevage and M&G join our shareholder register."
John Marotta, Executive in Residence, Patient Square Capital, said: "This investment reflects strong conviction in synthetic DNA's potential to advance novel healthcare treatments, and its place as a significant part of the cell and gene therapy market. We are well aligned with the team at 4basebio and are eager to help them reach their next phase of growth with this investment."
M&G Portfolio Manager, Jeremy Punnett, said: "The UK has a wealth of innovative deep tech firms that are breaking the mould, but it is vital they get the long-term investment they need to become the next global champions. M&G's Crossover strategy is playing a leading role in helping businesses to scale and thrive by providing expertise and patient capital.
"We are delighted to partner with Elevage in supporting 4basebio's pioneering work in synthetic DNA, which underpins the development of cell and gene therapies and offers the potential to transform healthcare and save millions of lives. We look forward to being part of their exciting journey and contributing to the advancement of cutting-edge therapies." |
More news to drop? Nice rise out of the blue... |
RNS re Tier 1 Pharma
Good news just keeps coming. |
Here's the CEO of Helixnano on the trials; |
Dont I know it!!! |
chicken charlie is |
You are right great RNS.
Are you a holder I do not check in that often as I do not think anyone else is in this? |
Looks like you will be fine. Nice rns this morning. |
An all time high.........Huzzah! |
A profit is a profit, well done!
I am in for the long haul!
Wish me luck! |
BUzzzz - sorry for delay no I am not. Watching with interest but I exited with a good profit after a portfolio review. |
Todays RNS is a clear signal the company is for sale.
Question is at what price and what timeframe , CEO and CFO have a great incentive looking at the bonus stated in the RNS.
Interesting times! |
Zours increasing his holding through Delphi.........must be confident! |
A bit of coverage for the sector. |
pob69
Thanks for posting! |
Finncap comment;
...results reflect consistent progress towards its main objective of producing GMP-grade synthetic DNA, while at the same time it is building incremental value into the business through product/technology expansion with first commercial sales of its DNA and increasing corporate partnerships. It generated revenues of £0.15m with adjusted pre-tax loss of £2.7m (H1 2021: £1.8m, +45%) and ended the period with £5.6m cash. Despite the expected increase in cashburn as headcount increases, near-term funding is not considered an issue, given that it can draw down from its €25m loan facility.
...minor changes to forecasts to reflect increased headcount and higher capex, with year-end cash forecast to be £1.9m (previously £2.3m). We maintain our sum-of-the-parts DCF target price of 1,200p, which is underpinned by the expected high demand for DNA/RNA and the significant potential of its technology to address key challenges in the cell and gene therapy space. |
Good to hear Buzz. Looking forward to how this interesting company progresses over next few years. |
Well done Hydrus.
I went to the AGM steady progress being made. |
Great recovery here - still holding |
free stock charts from uk.advfn.com |
Nice rise, downtrend broken! |
Nice to see the CFO pick up another 5,000 shares in June.
Management certainly putting their money where their mouth is!
Decent buying today pushing price back up. |
RNS 11th and 12th May.
Looks like they were able to buy after the results.
I will probably go to the AGM. |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
